Diuretics Market Report 2026

The diuretics market size has grown steadily in recent years. It will grow from $0.77 billion in 2025 to $0.79 billion in 2026 at a compound annual growth rate (CAGR) of 2.9%. The growth in the historic period can be attributed to high cardiovascular disease burden, widespread hospital prescriptions, long-standing clinical use, availability of low-cost generics, aging population.

The diuretics market size is expected to see steady growth in the next few years. It will grow to $0.92 billion in 2030 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to growth in chronic kidney disease cases, rising heart failure prevalence, expansion of primary healthcare access, improved treatment guidelines, increased geriatric population. Major trends in the forecast period include rising use in hypertension management, increased adoption of combination diuretic therapy, growth in generic diuretic drugs, expansion of outpatient treatment settings, improved formulations with reduced side effects.

The rise in renal and kidney disorder cases is expected to drive growth in the diuretics market in the coming years. These disorders affect the body’s ability to maintain fluid and electrolyte balance, often resulting in conditions such as edema, hypertension, and fluid retention, which require diuretics for proper management. The increase in kidney disorders is largely linked to lifestyle changes, including the consumption of unhealthy foods high in calcium and other minerals. The growing prevalence of kidney disorders supports the diuretics market by boosting the demand for medications that help remove excess fluid, reduce swelling, and regulate blood pressure in affected patients. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, reported that approximately 14% of U.S. adults, or around 35.5 million people, are living with chronic kidney disease. Thus, the rising incidence of renal and kidney disorders is a key factor driving the expansion of the diuretics market.

Major companies operating in the diuretics market are concentrating on developing innovative products, such as prescription medications, to improve treatment effectiveness and minimize side effects for patients with conditions like hypertension and heart failure. Prescription medications are drugs that require a doctor's prescription, ensuring they are used correctly for specific medical conditions under professional guidance. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, introduced a generic version of the diuretic Bumetanide Injection for managing fluid retention and swelling associated with congestive heart failure and other conditions. This product is offered in two formulations: 1 mg/4 mL single-dose vials and 2.5 mg/10 mL multi-dose vials, both with a concentration of 0.25 mg/mL. This injection is used to effectively address edema (fluid retention) caused by conditions such as congestive heart failure, liver disease, and kidney disease, promoting increased urine output to relieve symptoms like swelling and difficulty breathing.

In April 2025, Lupin Healthcare (UK) Limited, a UK-based provider of specialty and branded generic pharmaceutical products, acquired Renascience Pharma Limited for an undisclosed sum. Through this acquisition, Lupin aims to expand its specialty branded pharmaceuticals portfolio and enhance its commercial presence in the UK market. Renascience Pharma Limited is a UK-based provider of niche branded generics specializing in infectious disease, pain management, and cardiology/nephrology products, including quinazoline-like diuretics.

Major companies operating in the diuretics market are Merck & Co. Inc., Meda Manufacturing GmbH, Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, Aton Pharma Inc., Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi-aventis U.S. LLC, Centaur Pharmaceuticals Pvt Ltd, Validus Pharmaceuticals LLC, Actavis Generics, Paddock Laboratories LLC, Perrigo Pharmaceutical Company, Oak Pharmaceuticals Inc., Akron Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Aurobindo Pharma Limited, IPCA Laboratories Limited, Jubilant Cadista Pharmaceuticals Limited, Mylan N.V., Princeton Laboratories Inc., Sciegen Pharma Limited, Unichem Laboratories Limited, AstraZeneca plc, Bayer AG, Cipla Ltd, Fresenius Kabi AG, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

North America was the largest region in the diuretics market in 2025. The Middle East is expected to be the fastest-growing region in the diuretics market during the forecast period. The regions covered in the diuretics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diuretics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the diuretics market by increasing the cost of imported active pharmaceutical ingredients, chemical intermediates, and formulation excipients used in osmotic, loop, and thiazide diuretics. Hospital pharmacies and retail pharmacies in North America and Asia-Pacific are most affected due to their reliance on global generic drug supply chains. Applications such as hypertension and heart failure treatment face cost pressures from higher drug procurement prices. However, tariffs are encouraging domestic production of generic diuretics and boosting local pharmaceutical manufacturing capacity, improving long-term supply resilience.

The diuretics market research report is one of a series of new reports that provides diuretics market statistics, including diuretics industry global market size, regional shares, competitors with a diuretics market share, detailed diuretics market segments, market trends and opportunities, and any further data you may need to thrive in the diuretics industry. This diuretics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diuretic drugs are medications that help increase urine output by lowering the levels of sodium and chloride in the body. They assist the body in removing salt (sodium) and water, which is why they are often called ‘water tablets.’ Examples of diuretic drugs include Diuril, Microzide, and Indapamide.

The primary categories of diuretics include osmotic diuretics, carbonic anhydrase inhibitors, loop diuretics, thiazides and thiazide-like diuretics, and aldosterone antagonists. An osmotic diuretic is a type of diuretic that inhibits the reabsorption of water and sodium. These are pharmacologically inactive compounds administered intravenously. The available routes of administration include intravenous and oral, and they are utilized in conditions such as hypertension, glaucoma, heart failure, and kidney stones. They are distributed through multiple channels, including hospital pharmacies, independent pharmacies, retail pharmacies, drug stores, and online pharmacies.

The diuretics market consists of sales of diuril, microzide, and indapamide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.